Sysmex, AdnaGen team up for cancer Dx pact
This article was originally published in Clinica
Diagnostics firm Sysmex has signed a non-exclusive European distribution agreement with biotechnology research firm AdnaGen, for all of the latter’s current and future CE-marked diagnostics and research-only products. AdnaGen (Langenhagen, Germany) develops the AdnaTest line of diagnostic and analytical products for improving the prognosis and patient management breast and colon cancer. According to Sysmex, the tests are based on immunomagnetic selection of tumour cells from blood and the detection of tumour-specific markers using RT-PCR amplification techniques. Financial terms of the deal were not disclosed. This is Sysmex’s third collaboration in the diagnostics field in 2009. In January, the Kobe, Japan-based company partnered with Epigenomics for the detection of methylated DNA in blood, and Oncolys Biopharma, to develop and commercialise an in vitro cancer diagnostic agent.
You may also be interested in...
Alere’s professional diagnostics business helped the firm record overall revenue growth in the fourth quarter of 2010, offsetting a fall in influenza-based sales in North America.
Integra LifeSciences has gained exclusive worldwide rights from Stout Medical to develop and commercialise an expandable interbody fusion device.
Gen-Probe recently launched its Panther automated molecular diagnostics system in Europe with the aim of bringing another dimension to its product portfolio. Joseph Harvey met the firm’s CEO, Carl Hull, at the launch of the product in Frankfurt to find how high the firm has set its sights in the molecular diagnostics sector and how it is going to achieve its goals